scholarly journals Idiopathic Sclerosing Mesenteritis: An Extremely Rare Cause of Mesenteric Mass

2021 ◽  
Vol 12 (12) ◽  
pp. 516-519
Author(s):  
Samyak Dhruv ◽  
Meena Kashi ◽  
Dhwani Pandya
Keyword(s):  
Sclerosing Mesenteritis ◽  
Mesenteric Mass

scholarly journals Sclerosing Mesenteritis, a Rare Cause of Mesenteric Mass in a Young Adult: A Case Report

2021 ◽  
Vol 8 ◽  
Author(s):  
Eliana Piombino ◽  
Costanza D'Agata ◽  
Maria Carolina Picardo ◽  
Claudia Caltavuturo ◽  
Gaetano Magro ◽  
...  
Keyword(s):  
Weight Loss ◽  
Plasma Cells ◽  
Abdominal Mass ◽  
Correct Diagnosis ◽  
Inflammatory Cells ◽  
Mass Effect ◽  
Sclerosing Mesenteritis ◽  
Rapid Weight Loss ◽  
Eosinophilic Cytoplasm ◽  
Mesenteric Mass

Sclerosing mesenteritis (SM) is a rare fibroinflammatory disorder that involves mesenteric adipose tissue, more frequently localized in the small intestine, with an insidious clinical presentation having symptoms related to mass effect, usually resulting in bowel obstruction, mesenteric ischemia, as well as rapid weight loss. We report a case of a 23-year-old male presenting with palpable abdominal mass, mesogastric pain, and a history of rapid weight loss, who underwent exploratory laparoscopy. A hemorrhagic and gelatinous nodular tumor mass of the mesentery was identified and the surgical procedure was converted to a laparotomic approach. Histologically, the mass was composed of a proliferation of bland-looking spindle cells with slightly eosinophilic cytoplasm and elongated normochromatic nuclei with mild nuclear atypia, haphazardly set in a collagenized stroma; fat necrosis and inflammatory cells (lymphocytes, plasma-cells, and histiocytes) were also evident. The diagnosis of sclerosing mesenteritis was made. Our case emphasizes that histology remains pre-eminent for a correct diagnosis of SM, as pre-operative radiological-based diagnosis is non-specific.

scholarly journals Surgical Excision of Sclerosing Mesenteritis, Exploration of an Unknown Mesenteric Mass

Cureus ◽  
2021 ◽  
Author(s):  
Thomas J Serena ◽  
Carolyn A Solomon Schnurr ◽  
John C Pui ◽  
Jeffrey R Gerken
Keyword(s):  
Surgical Excision ◽  
Sclerosing Mesenteritis ◽  
Mesenteric Mass

Four Cases of Postoperative Sclerosing Mesenteritis

2007 ◽  
Vol 23 (5) ◽  
pp. 374 ◽  
Author(s):  
Eu Gene Kim ◽  
Yong Won Kang ◽  
Seo Gu Yoon ◽  
Heung Dai Kim ◽  
Kwang Yun Kim
Keyword(s):  
Sclerosing Mesenteritis

Colchicine as an Alternative First-Line Treatment of Sclerosing Mesenteritis: A Retrospective Study

2021 ◽  
Author(s):  
Pedro Cortés ◽  
Hassan M. Ghoz ◽  
Obaie Mzaik ◽  
Muhamad Alhaj Moustafa ◽  
Yan Bi ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Sclerosing Mesenteritis ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 443
Author(s):  
Anela Blažević ◽  
Tessa Brabander ◽  
Wouter T. Zandee ◽  
Johannes Hofland ◽  
Gaston J. H. Franssen ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Size Reduction ◽  
Static Behavior ◽  
Recist 1.1 ◽  
Mesenteric Mass ◽  
Small Intestinal ◽  
Objective Size ◽  
Over Time

Background: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known on its development over time. Therefore, we conducted a study to assess the evolution of a SI-NET-associated mesenteric mass over time. Methods: Retrospectively, 530 patients with proven SI-NET were included. The presence and growth of a mesenteric mass was assessed using RECIST 1.1 criteria on every consecutive CT-scan until the end of follow-up or resection. Results: At baseline, a mesenteric mass was present in 64% of the patients, of whom 13.5% showed growth of the mesenteric mass with a median time to growth of 40 months. Male gender was the only independent predictor of growth (OR 2.67). Of the patients without a mesenteric mass at the first evaluation, 2.6% developed a pathological mesenteric mass. Treatment with peptide receptor radionuclide therapy (PRRT; N = 132) resulted in an objective size reduction of the mesenteric mass in 3.8%. Conclusion: The metastatic mesenteric mass in SI-NETs has a static behavior over time. Therefore, site-specific growth behavior should be taken into account when selecting target lesions and assessing disease progression and therapeutic response. PRRT appears not to be effective for size reduction of the mesenteric mass.

scholarly journals AB1056 SYMPTOMATIC SCLEROSING MESENTERITIS REVEALING ERDHEIM-CHESTER DISEASE: A RARE CONDITION MEDIATED BY BRAF

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1818.1-1818
Author(s):  
J. Razanamahery ◽  
S. Humbert ◽  
A. Malakhia ◽  
J. F. Emile ◽  
F. Cohen ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Sclerosing Mesenteritis ◽  
Fat Infiltration ◽  
Abdominal Computed Tomography ◽  
Erdheim Chester Disease ◽  
Mutational Status ◽  
The Mean ◽  
Kinase Pathway ◽  
Erdheim Chester ◽  
Chester Disease

Background:Sclerosing Mesenteritis (SM) refers to an entire spectrum of digestive inflammatory disorders. Diagnosis is based on imaging showing an increase of fat attenuation displacing bowel loops and is in most cases non-symptomatic. Several conditions (abdominal trauma/surgery, neoplasia, infectious and inflammatory diseases) are responsible for SM (1). Among neoplasia, Erdheim-Chester disease (ECD) is a rare clonal histiocytosis characterized by long bone involvement, peri-nephric fat infiltration and cardio-vascular involvement associated with compatible histology (2). Biopsy is mandatory to confirm tissue infiltration by histiocytes and detect somatic mutation. Almost 80% of ECDpatients harbor mutation in mitogen activated protein(MAP) kinase pathway especiallyBRAFV600Egene mutation in about 60% of cases(3). No series of patients presenting both pathologies has been reported. Furthermore, no correlation withBRAFmutation status has been described in patient harboring SM and ECD.Objectives:To describe the clinical, radiological and mutational status of patients harboring SM and ECD.Methods:We reviewed the database of patients with histiocytic disorders in Besancon University Hospital. Patient required one abdominal computed tomography showing sclerosing mesenteritis and clinical/histological features of ECD to fulfill the inclusion criteria. All biopsy samples were investigated for mutation ofMAPkinase pathway gene.Results:Four patients suffered from SM and ECD. The median age at the diagnosis of ECD was 68 years old (61-72). All patients described abdominal pain and the mean duration between first symptoms and diagnosis of ECD was 12 months (4-19). The mean CRP level at diagnosis was 40.75 mg/L (5-117). Two patients were found to have myeloid neoplasms (chronic myelomonocytic leukemia (#2) and essential thrombocythemia (#4)) concurrent with ECD diagnosis.Regarding abdominal computed tomography, all patients had a mesenteric mass associated with hyper-attenuated mesenteric fat and a “fat halo sign”. One patient (#2) had ascites and one had splenomegaly (#4) but no patient had enlarged lymph nodes. CT also demonstrated peri-nephric fat infiltration (“hairy kidney”) (4/4), vascular sheathing of aortic branches (3/4), adrenal hypertrophy (1/4) or ureter dilation (1/4). The mean SUVmaxof the mesentery was 7.5 (4.1-10.9) at diagnosis on (18F)- fluorodeoxyglucose-PET. Three patients underwent mesentery fat biopsy and all samples exhibited ECD histology. Regarding mutational status, 75% (3/4) patients hadBRAFV600Emutation.After initiation of therapies for ECD (targeted therapies for ¾ patients), all patients had improvement of digestive symptoms and decreased of SUVmaxon evaluation18FDG-PET during the follow up.Conclusion:ECD should be investigated in patient with symptomatic SM especially if it is associated with peri-nephric fat infiltration. This condition is rare and might be driven by BRAF gene.TABLE 2.Full term pregnancyMultiple gestationPreconception CZP exposureLabor complicationsMaternal infectionsNeonatal infections (< 6 m after birth)Congenital malformationsBreast-feedingNeonates, n/N15/152/155/150/151/150/150/156/15References:[1]Danford CJ, Lin SC, Wolf JL. Sclerosing Mesenteritis. Am J Gastroenterol. 2019 Jun;114(6):867–73.[2]Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014 Jul 24;124(4):483–92.[3]Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017 Feb;18(2):e113–25.Disclosure of Interests:None declared

scholarly journals Sclerosing Mesenteritis: Diverse clinical presentations and dissimilar treatment options. A case series and review of the literature

2011 ◽  
Vol 4 (1) ◽  
pp. 17 ◽  
Author(s):  
Konstantinos Vlachos ◽  
Fotis Archontovasilis ◽  
Evangelos Falidas ◽  
Stavros Mathioulakis ◽  
Stefanos Konstandoudakis ◽  
...  
Keyword(s):  
Treatment Options ◽  
Case Series ◽  
Sclerosing Mesenteritis ◽  
Review Of The Literature ◽  
Clinical Presentations

Chronic anisakiasis presenting as a mesenteric mass

2000 ◽  
Vol 25 (5) ◽  
pp. 548-550 ◽  
Author(s):  
M. Céspedes ◽  
A. Saez ◽  
I. Rodríguez ◽  
J. M. Pinto ◽  
R. Rodríguez
Keyword(s):  
Mesenteric Mass

scholarly journals MR findings in a rare case of sclerosing mesenteritis of the mesocolon

2005 ◽  
Vol 21 (5) ◽  
pp. 632-636 ◽  
Author(s):  
Nadir Ghanem ◽  
Gregor Pache ◽  
Thorsten Bley ◽  
Elmar Kotter ◽  
Mathias Langer
Keyword(s):  
Rare Case ◽  
Sclerosing Mesenteritis
Sign in / Sign up

Export Citation Format

Share Document